IL-4 and IL-13 induce protection of porcine endothelial cells from killing by human complement and from apoptosis through activation of a phosphatidylinositide 3-kinase/Akt pathway.
Vascular endothelial cells (EC) perform critical functions that require a balance of cell survival and cell death. EC death by apoptosis and EC activation and injury by the membrane attack complex of complement are important mechanisms in atherosclerosis and organ graft rejection. Although the effects of various cytokines on EC apoptosis have been studied, little is known about their effects on complement-mediated EC injury. Therefore, we studied the abilities of various cytokines to induce protection of porcine aortic EC against apoptosis and killing by human complement, a model of pig-to-human xenotransplantation. We found that porcine EC incubated with IL-4 or IL-13, but not with IL-10 or IL-11, became protected from killing by complement and apoptosis induced by TNF-alpha plus cycloheximide. Maximal protection required 10 ng/ml IL-4 or IL-13, developed progressively from 12 to 72 h of incubation, and lasted 48-72 h after cytokine removal. Protection from complement was not associated with reduced complement activation, C9 binding, or changes in CD59 expression. Inhibition of PI3K prevented development of protection; however, inhibition of p38 MAPK or p42/44 MAPK had no effect. IL-4 and IL-13 induced rapid phosphorylation of Akt. Although protection was inhibited by an Akt inhibitor and a dominant negative Akt mutant transduced into EC, it was induced by transduction of EC with the constitutively active Akt variant, myristylated Akt. We conclude that IL-4 and IL-13 can induce protection of porcine EC against killing by apoptosis and human complement through activation of the PI3K/Akt signaling pathway.
Grehan
John F
JF
Department of Surgery, University of Minnesota School of Medicine, Minneapolis, MN 55455, USA.
Levay-Young
Brett K
BK
Fogelson
Jeremy L
JL
François-Bongarçon
Vanessa
V
Benson
Barbara A
BA
Dalmasso
Agustin P
AP
D000818:Animals; D017209:Apoptosis / Q000276:immunology*; D018957:CD59 Antigens / Q000096:biosynthesis; D002478:Cells, Cultured; D003167:Complement Activation / Q000276:immunology*; D003186:Complement C9 / Q000378:metabolism; D003513:Cycloheximide / Q000037:antagonists & inhibitors / Q000633:toxicity; D003602:Cytotoxicity, Immunologic / Q000276:immunology*; D004730:Endothelium, Vascular / Q000201:enzymology / Q000276:immunology* / Q000378:metabolism / Q000473:pathology; D006801:Humans; D018793:Interleukin-13 / Q000502:physiology*; D015847:Interleukin-4 / Q000502:physiology*; D020935:MAP Kinase Signaling System / Q000276:immunology; D009336:Necrosis; D019869:Phosphatidylinositol 3-Kinases / Q000502:physiology*; D010766:Phosphorylation; D011485:Protein Binding / Q000276:immunology; D017346:Protein Serine-Threonine Kinases / Q000378:metabolism / Q000502:physiology*; D011518:Proto-Oncogene Proteins / Q000378:metabolism / Q000502:physiology*; D051057:Proto-Oncogene Proteins c-akt; D013552:Swine; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000633:toxicity
D018957:CD59 Antigens; D003186:Complement C9; D003513:Cycloheximide; D018793:Interleukin-13; D015847:Interleukin-4; D019869:Phosphatidylinositol 3-Kinases; D017346:Protein Serine-Threonine Kinases; D011518:Proto-Oncogene Proteins; D051057:Proto-Oncogene Proteins c-akt; D014409:Tumor Necrosis Factor-alpha; C494918:AKT1 protein, human